Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

Aim The aim of this study is to assess the efficacy and safety of vildagliptin 50?mg bid as add-on therapy to insulin in type 2 diabetes mellitus (T2DM). Methods This is a multicentre, double-blind, placebo-controlled, parallel group, clinical trial in T2DM patients inadequately controlled by stable insulin therapy, with or without metformin. Patients received treatment with vildagliptin 50?mg bid or placebo for 24?weeks. Results In all, 449 patients were randomized to vildagliptin (n?=?228) or placebo (n?=?221). After 24?weeks, the difference in adjusted mean change in haemoglobin A1c (HbA1c) between vildagliptin and placebo was -0.7 +/- 0.1% (p?